Stoke Therapeutics Inc (STOK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Stoke Therapeutics Inc (STOK) has a cash flow conversion efficiency ratio of -0.153x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-60.58 Million) by net assets ($394.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See STOK net asset quality score to measure how much of total assets are equity-financed.
Stoke Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Stoke Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check STOK cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Stoke Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Stoke Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LDR Turizm AS
IS:LIDER
|
0.160x |
|
SK Bioscience Co Ltd
KO:302440
|
0.010x |
|
Jiangsu Eazytec Co Ltd
SHG:688258
|
0.025x |
|
Hangzhou Shunwang Tech
SHE:300113
|
0.046x |
|
Garware Hi-Tech Films Limited
NSE:GRWRHITECH
|
0.061x |
|
SJW Group Common Stock
NYSE:SJW
|
0.031x |
|
Pimco Dynamic Income Opportunities Fund
NYSE:PDO
|
0.276x |
|
DRDGOLD Limited
F:DUBA
|
0.066x |
Annual Cash Flow Conversion Efficiency for Stoke Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Stoke Therapeutics Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Stoke Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $352.46 Million | $45.59 Million | 0.129x | +134.10% |
| 2024-12-31 | $229.02 Million | $-86.85 Million | -0.379x | +25.36% |
| 2023-12-31 | $159.56 Million | $-81.07 Million | -0.508x | -194.71% |
| 2022-12-31 | $184.85 Million | $-31.87 Million | -0.172x | +43.89% |
| 2021-12-31 | $217.78 Million | $-66.91 Million | -0.307x | -108.17% |
| 2020-12-31 | $286.08 Million | $-42.22 Million | -0.148x | -6.66% |
| 2019-12-31 | $224.43 Million | $-31.05 Million | -0.138x | -32.60% |
| 2018-12-31 | $105.07 Million | $-10.96 Million | -0.104x | -102.50% |
| 2017-12-31 | $-1.29 Million | $-5.38 Million | 4.167x | -- |
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials fo… Read more